Black Diamond Therapeutics Inc
BDTX2.815USD
+0.225+8.69%
交易中 （美东）报价延迟15分钟
159.54M总市值
31.34市盈率 TTM
关于 Black Diamond Therapeutics Inc 公司
Black Diamond Therapeutics, Inc. 是一家临床阶段肿瘤学公司，专注于开发 MasterKey 疗法，以解决临床验证靶点中的致癌突变家族。该公司的 MasterKey 疗法旨在解决广泛的基因定义的患者群体，克服耐药性，最大限度地减少野生型介导的毒性，并具有脑渗透性以治疗中枢神经系统 (CNS) 疾病。该公司正在推进两个临床阶段项目：BDTX-1535，一种脑渗透性第四代表皮生长因子受体 (EGFR) MasterKey 抑制剂，针对 EGFR 突变型非小细胞肺癌 (NSCLC) 和胶质母细胞瘤 (GBM)，以及 BDTX-4933，一种脑渗透性 RAF MasterKey 抑制剂，针对实体瘤中的 KRAS、NRAS 和 BRAF 变异。其 BDTX-4876 是一种致癌 FGFR2/3 突变的 MasterKey 抑制剂，与 FGFR1/4 相比具有选择性。该公司还专注于针对未公开的、已验证的致癌基因的候选药物的开发。
公司简介
公司代码BDTX
公司名称Black Diamond Therapeutics Inc
上市日期Jan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
员工数量24
证券类型Ordinary Share
年结日Jan 30
公司地址One Main Street, 14th Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话16174175868
网址https://www.blackdiamondtherapeutics.com/
公司代码BDTX
上市日期Jan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
股东类型
持股股东
占比
Investment Advisor
36.89%
Venture Capital
18.81%
Investment Advisor/Hedge Fund
18.59%
Hedge Fund
7.37%
Research Firm
1.43%
Individual Investor
0.96%
Bank and Trust
0.18%
Pension Fund
0.02%
Other
15.76%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
254
48.67M
85.58%
-26.49M
2025Q1
261
50.38M
88.73%
-26.95M
2024Q4
246
57.08M
100.88%
-16.52M
2024Q3
250
57.38M
101.59%
-12.76M
2024Q2
242
55.35M
99.47%
-3.18M
2024Q1
244
48.01M
92.96%
-13.90M
2023Q4
235
47.28M
91.68%
-8.00M
2023Q3
256
45.71M
88.75%
-9.85M
2023Q2
259
50.33M
103.17%
+16.38M
2023Q1
277
29.49M
80.76%
-7.91M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
10.40M
18.29%
-67.48K
-0.64%
Mar 31, 2025
Versant Ventures
6.21M
10.92%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.60M
9.85%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
4.45M
7.82%
--
--
Apr 11, 2025
Bellevue Asset Management AG
2.73M
4.81%
-5.78M
-67.91%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.36M
4.15%
-47.11K
-1.96%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.14%
-57.11K
-2.37%
Mar 31, 2025
Tang Capital Management, LLC
2.07M
3.64%
--
--
Mar 31, 2025
Millennium Management LLC
1.10M
1.94%
+545.84K
+97.81%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Health Innovation Active ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
查看更多
Fidelity Enhanced Small Cap ETF
占比0.04%
iShares Micro-Cap ETF
占比0.03%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
iShares Russell 2000 Growth ETF
占比0%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
iShares Health Innovation Active ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
